Close Menu

NEW YORK (GenomeWeb) – Biocept reported after the close of the market on Wednesday that its second quarter revenues dropped 23 percent year over year.

For the three months ended June 30, the San Diego-based liquid biopsy firm had $917,471 in revenues compared to the $1.2 million it saw during the same quarter last year. These included $841,000 in commercial test revenue, $38,000 in development services test revenue, and $38,000 in revenue for distributed products, split between Biocept's Target Selector RUO kits and CEE-Sure blood collection tubes.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.